Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection

被引:31
作者
Fu, Wei [1 ]
Song, Zhiqiang [1 ]
Zhou, Liya [1 ]
Xue, Yan [1 ]
Ding, Yu [1 ]
Suo, Baojun [1 ]
Tian, Xueli [1 ]
Wang, Li [1 ]
机构
[1] Peking Univ, Hosp 3, Dept Gastroenterol, 49 North Garden Rd, Beijing 100191, Peoples R China
关键词
Helicobacter pylori; Eradication; Amoxicillin; Cefuroxime; Safety; Compliance; PENICILLIN-ALLERGIC PATIENTS; TRIPLE PLUS BISMUTH; ANTIBIOTIC-RESISTANCE; THERAPY; MANAGEMENT; CEPHALOSPORINS; CLARITHROMYCIN; METRONIDAZOLE; MULTICENTER; EFFICACY;
D O I
10.1007/s10620-017-4564-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The eradication of Helicobacter pylori infection remains a challenge, especially in the patients unsuitable to take penicillin. Cephalosporin has the potential to replace amoxicillin for H. pylori eradication. To compare the effectiveness, safety, and compliance of amoxicillin- and cefuroxime-containing quadruple regimens in treatment-na < ve patients. In this open-label randomized control study, 400 patients with H. pylori infection were divided into amoxicillin-containing (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) or cefuroxime-containing (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) quadruple therapy groups. The safety and compliance were assessed 1-3 days after eradication. Urea breath test was performed 8-12 weeks after eradication to determine treatment outcome. The baseline data including antibiotic resistance were well matched between the two groups. The eradication rates between amoxicillin- and cefuroxime-containing quadruple therapy groups were not significantly different [intention-to-treat analysis: 83.5% (95% confidence interval 78.3-88.7%) vs. 81.0% (75.5-86.5%), P = 0.513; modified intention-to-treat analysis: 90.3% (86.0-94.6%) vs. 88.5% (83.9-93.2%), P = 0.586; per-protocol analysis: 91.6% (87.5-95.7%) vs. 89.8% (85.3-94.3%), P = 0.560]. The incidence of adverse effects (18.4 vs. 20.1%, P = 0.678) and compliance (94.7 vs. 94.2%, P = 0.813) were also similar. Variate analyses showed that antibiotic resistance and poor compliance were the independent risk factors for eradication failure. Esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime achieved similar and relatively satisfactory cure rates, safety, and compliance in first-line H. pylori eradication. Cefuroxime may be a good alternative medicine for eradication instead of amoxicillin for the patients unsuitable to take penicillin.
引用
收藏
页码:1580 / 1589
页数:10
相关论文
共 50 条
  • [21] The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication A multicenter, randomized, controlled clinical trial
    Cao, Yaping
    Zhang, Jian
    Liu, Yuan
    Zhang, Lifeng
    Wang, Lu
    Wang, Jie
    Qi, Ying
    Lv, Huanhuan
    Liu, Juan
    Huo, Lijuan
    Wei, Xiaoguo
    Shi, Yongquan
    MEDICINE, 2021, 100 (50)
  • [22] Clarithromycin versus levofloxacin-based regimens for Helicobacter pylori eradication in the Kurdistan Region of Iraq: A randomized clinical trial
    Mohammed, Shinah A.
    Al-Iela, Omer Q. B.
    Hussein, Nawfal R.
    Hajany, Ramadhan S.
    Alduhoky, Laween S.
    GASTROENTEROLOGY INSIGHTS, 2019, 10 (01)
  • [23] Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of Helicobacter pylori Infection
    Miehlke, Stephan
    Krasz, Susanne
    Schneider-Brachert, Wulf
    Kuhlisch, Eberhard
    Berning, Marco
    Madisch, Ahmed
    Laass, Martin W.
    Neumeyer, Michael
    Jebens, Claus
    Zekorn, Christian
    Knoth, Holger
    Vieth, Michael
    Stolte, Manfred
    Lehn, Norbert
    Morgner, Andrea
    HELICOBACTER, 2011, 16 (06) : 420 - 426
  • [24] Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial
    Kefeli, Ayse
    Basyigit, Sebahat
    Yeniova, Abdullah Ozgur
    Kefeli, Tarik Tayfur
    Aslan, Muzaffer
    Tanas, Ozlem
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2016, 16 (01) : 52 - 57
  • [25] First-line Bismuth-containing Five-day Concomitant Quintuple Therapy for Helicobacter Pylori Eradication
    Dolapcioglu, Can
    Sayiner, Mehmet
    Akkus, Esra Elif
    Kural, Abdulaziz
    Dolapcioglu, Hatice
    Dabak, Resat
    Ahishali, Emel
    HELICOBACTER, 2016, 21 (02) : 100 - 105
  • [26] Levofloxacin-Based First-Line Therapy versus Standard First-Line Therapy for Helicobacter pylori Eradication: Meta-Analysis of Randomized Controlled Trials
    Peedikayil, Musthafa Chalikandy
    AlSohaibani, Fahad Ibrahim
    Alkhenizan, Abdullah Hamad
    PLOS ONE, 2014, 9 (01):
  • [27] The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication
    Akyildiz, Murat
    Akay, Sinan
    Musoglu, Ahmet
    Tuncyurek, Muge
    Aydin, Ahmet
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 (01) : 53 - 57
  • [28] Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication
    Ye, Jian Fang
    Hong, Jun Bo
    Zhu, Yin
    Xie, Yong
    Shu, Xu
    Luo, Ling Yu
    Xie, Chuan
    Zhu, Zhen Hua
    Lu, Nong Hua
    JOURNAL OF DIGESTIVE DISEASES, 2017, 18 (12) : 704 - 708
  • [29] Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication A Multicenter, Prospective, Randomized Controlled Study in Japan
    Nishizawa, Toshihiro
    Maekawa, Takama
    Watanabe, Noriko
    Harada, Naohiko
    Hosoda, Yasuo
    Yoshinaga, Masahiro
    Yoshio, Toshiyuki
    Ohta, Hajime
    Inoue, Syuuji
    Toyokawa, Tatsuya
    Yamashita, Haruhiro
    Saito, Hiroki
    Kuwai, Toshio
    Katayama, Shunsuke
    Masuda, Eiji
    Miyabayashi, Hideharu
    Kimura, Toshio
    Nishizawa, Yuko
    Takahashi, Masahiko
    Suzuki, Hidekazu
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (06) : 468 - 471
  • [30] Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
    Ju Yup Lee
    Nayoung Kim
    Kyung Sik Park
    Hyun Jin Kim
    Seon Mee Park
    Gwang Ho Baik
    Ki-Nam Shim
    Jung Hwan Oh
    Suck Chei Choi
    Sung Eun Kim
    Won Hee Kim
    Seon-Young Park
    Gwang Ha Kim
    Bong Eun Lee
    Yunju Jo
    Su Jin Hong
    BMC Gastroenterology, 16